Rajasthan govt halts distribution of all 19 medicines supplied by Kayson Pharma

Rajasthan government has suspended Drug Controller Rajaram Sharma and halted the distribution of all 19 medicines supplied by Kayson Pharma.

The action was taken after two children died and several fell ill, allegedly due to the consumption of cough syrups distributed under the Chief Minister’s Free Medicine Scheme.

The Health Department cited quality control failures. The state has also banned the supply of cough syrups containing dextromethorphan from all manufacturers after several batches failed quality tests.

According to Rajasthan Medical Services Corporation Limited, 10 thousand 119 samples of Kayson Pharma’s medicines have been tested since 2012, with 42 found to be substandard. Chief Minister Bhajan Lal Sharma has ordered a detailed investigation into the issue.

An expert committee is being formed to examine how the medicines passed existing checks and what failures occurred in the quality assurance process.

Related Posts

Rajasthan Bans 7 Sub-Standard Medicines

Prioritising public health and patient safety, the Commissionerate of Food Safety and Drug Control, Rajasthan, has issued an alert regarding seven medicines and declared them “Not of Standard Quality”. Prioritising…

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

Rajasthan Bans 7 Sub-Standard Medicines

Rajasthan Bans 7 Sub-Standard Medicines

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23